Its anticholestatic effect and that of the PPARα agonist fenofibrate has since then been documented in various small trials (185), and finally in a prospective, randomized, placebo-controlled study in 100 patients with PBC treated over 2 years (108, 186) convincingly confirmed. This evidence concerns the gene PPARA and primary biliary cholangitis.